載入中
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
最新資料
US$8.34
−US$0.32 · -3.70%
盤中時間採用ET。市場資料可能有所延遲。
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
營業利益
淨利
| 項目（CHF） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 68.6萬 CHF | — | — | — |
| 銷貨成本 | — | 5208.3萬 CHF | — | — | — |
| 毛利 | — | −5139.7萬 CHF | — | — | — |
| 研究與開發 | 5451.86萬 CHF | 5208.3萬 CHF | 2924.7萬 CHF | 2222.4萬 CHF | 956.8萬 CHF |
| 銷售、一般及管理費用 | 2462.67萬 CHF | 2180.7萬 CHF | 1472.4萬 CHF | 674.3萬 CHF | 409.7萬 CHF |
| 營業費用 | 7914.54萬 CHF | 2180.7萬 CHF | 8071.4萬 CHF | 3237.6萬 CHF | 1323.2萬 CHF |
| 利息收入 | 169.04萬 CHF | 216.8萬 CHF | 159.02萬 CHF | 12.6萬 CHF | 2.1萬 CHF |
| 利息支出 | 79.56萬 CHF | 63.9萬 CHF | 146.33萬 CHF | 644.2萬 CHF | 512萬 CHF |
| 折舊和攤銷 | 54.6萬 CHF | 40.6萬 CHF | 28.7萬 CHF | 29.9萬 CHF | 23.5萬 CHF |
| 營業利益 | −7914.54萬 CHF | −7320.4萬 CHF | −8071.4萬 CHF | −3237.6萬 CHF | −1323.2萬 CHF |
| 淨利 | −9450.82萬 CHF | −8577.7萬 CHF | −8880.2萬 CHF | −3869.8萬 CHF | −1855.2萬 CHF |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
